Biotech & Pharma

Novo Nordisk, Vivtex Ink Up to $2.1B Deal to Develop Oral Biologics for Metabolic Conditions

23 sec read5 views0 listens

Novo Nordisk and Vivtex have entered a $2.1 billion partnership to develop oral biologics for metabolic conditions like obesity and diabetes, leveraging Vivtex's gastrointestinal screening technology. This collaboration highlights the potential of oral delivery systems in expanding treatment options for these conditions, offering significant benefits over traditional injectable methods.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Ali NematiBlogUI.author_articles

BlogUI.view_profile

You Might Like

GitHub Trending3 hours ago34 sec read

bilawalsidhu/gods-eye-view — A spy satellite simulator in your browser, except the data is real. Live open so

8,746 stars | 1,906 forks | JavaScript A spy satellite simulator in your browser, except the data is real. Live open source spatial intelligence on a photorealistic 3D globe. What it does God's Eye View is a real-time, photorealistic 3D globe simulat...

Ali Nemati

Startups & VC4 hours ago27 sec read

The case for hybrid microfinance: Combining AI with social accountability

AI-driven microfinance products in Indonesia are using advanced data analytics to streamline lending processes, offering higher approval rates and lower origination costs compared to traditional methods. However, these systems risk undermining the so...

Ali Nemati

Startups & VC4 hours ago23 sec read

Language was never the problem: Inside SEA's real AI adoption gap

Kai Yong Kang, a partner at GenAI Fund, argues that the primary barrier to AI adoption in Southeast Asia is not language but enterprise trust and secure scalability. This shift highlights the need for deeper localisation efforts beyond mere translati...

Ali Nemati